Autolus Therapeutics Plc (AUTL) has released an update to notify the public and investors about an entry into a material definitive agreement.
Autolus Therapeutics plc has entered into an underwriting agreement with Jefferies LLC and Truist Securities, Inc., launching a registered direct offering of 58.3 million American Depositary Shares at $6.00 each, aiming to raise $350 million. The offering, detailed in a recent SEC filing, is set to close around February 12, 2024, with standard closing conditions. This significant financial move, underpinned by customary legal agreements, indicates a robust step for the company in securing its financial future.
For further insights into AUTL stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
